P3H4
gene geneOn this page
Also known as SC65NO55
Summary
P3H4 (prolyl 3-hydroxylase family member 4 (inactive), HGNC:16946) is a protein-coding gene on chromosome 17q21.2, encoding Endoplasmic reticulum protein SC65 (Q92791). Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linking of collagen fibrils.
This nucleolar protein was first characterized because it was an autoantigen in cases on interstitial cystitis. The protein, with a predicted molecular weight of 50 kDa, appears to be localized in the particulate compartment of the interphase nucleolus, with a distribution distinct from that of nucleolar protein B23. During mitosis it is associated with chromosomes.
Source: NCBI Gene 10609 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 75 total
- MANE Select transcript:
NM_006455
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:16946 |
| Approved symbol | P3H4 |
| Name | prolyl 3-hydroxylase family member 4 (inactive) |
| Location | 17q21.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | SC65, NO55 |
| Ensembl gene | ENSG00000141696 |
| Ensembl biotype | protein_coding |
| OMIM | 617419 |
| Entrez | 10609 |
Gene structure
Transcript identifiers
Ensembl transcripts: 18 — 14 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay
ENST00000355468, ENST00000393928, ENST00000465097, ENST00000467164, ENST00000484247, ENST00000587455, ENST00000590496, ENST00000592026, ENST00000891166, ENST00000914260, ENST00000914261, ENST00000914262, ENST00000914263, ENST00000914264, ENST00000914265, ENST00000970400, ENST00000970401, ENST00000970402
RefSeq mRNA: 1 — MANE Select: NM_006455
NM_006455
CCDS: CCDS11408
Canonical transcript exons
ENST00000393928 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002535992 | 41811454 | 41811949 |
| ENSE00003481276 | 41811132 | 41811284 |
| ENSE00003482294 | 41801953 | 41802979 |
| ENSE00003658933 | 41803287 | 41803431 |
| ENSE00003889819 | 41807859 | 41808004 |
| ENSE00003893760 | 41810863 | 41811034 |
| ENSE00003895606 | 41806796 | 41806879 |
| ENSE00003895803 | 41809706 | 41809834 |
Expression profiles
Bgee: expression breadth ubiquitous, 227 present calls, max score 96.08.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.3923 / max 102.3141, expressed in 1572 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 166047 | 13.8021 | 1569 |
| 166049 | 0.5902 | 393 |
Top tissues by expression
271 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| stromal cell of endometrium | CL:0002255 | 96.08 | gold quality |
| periodontal ligament | UBERON:0008266 | 89.12 | gold quality |
| tibia | UBERON:0000979 | 88.17 | gold quality |
| ventricular zone | UBERON:0003053 | 87.21 | gold quality |
| adenohypophysis | UBERON:0002196 | 85.74 | gold quality |
| pituitary gland | UBERON:0000007 | 85.44 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 85.30 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 85.13 | gold quality |
| left adrenal gland | UBERON:0001234 | 85.03 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 84.94 | silver quality |
| right adrenal gland | UBERON:0001233 | 84.68 | gold quality |
| body of pancreas | UBERON:0001150 | 84.66 | gold quality |
| ascending aorta | UBERON:0001496 | 84.44 | gold quality |
| thoracic aorta | UBERON:0001515 | 84.31 | gold quality |
| adrenal cortex | UBERON:0001235 | 84.24 | gold quality |
| right coronary artery | UBERON:0001625 | 84.11 | gold quality |
| cartilage tissue | UBERON:0002418 | 84.11 | gold quality |
| endocervix | UBERON:0000458 | 83.92 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 83.74 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 83.47 | gold quality |
| adrenal gland | UBERON:0002369 | 83.34 | gold quality |
| thyroid gland | UBERON:0002046 | 83.14 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 83.11 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 83.08 | gold quality |
| cerebellar cortex | UBERON:0002129 | 83.04 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 82.81 | gold quality |
| body of uterus | UBERON:0009853 | 82.44 | gold quality |
| metanephros cortex | UBERON:0010533 | 82.24 | gold quality |
| ectocervix | UBERON:0012249 | 82.22 | gold quality |
| right ovary | UBERON:0002118 | 82.16 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.99 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): ESR2
miRNA regulators (miRDB)
21 targeting P3H4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3924 | 100.00 | 72.09 | 2394 |
| HSA-MIR-4715-3P | 99.98 | 66.03 | 670 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-3529-3P | 99.90 | 73.55 | 3045 |
| HSA-MIR-3663-3P | 99.84 | 70.39 | 798 |
| HSA-MIR-3121-3P | 99.82 | 71.96 | 3630 |
| HSA-MIR-1827 | 99.63 | 68.57 | 3265 |
| HSA-MIR-7159-5P | 99.53 | 72.12 | 2472 |
| HSA-MIR-6878-3P | 99.24 | 64.23 | 920 |
| HSA-MIR-5584-3P | 99.23 | 68.79 | 1351 |
| HSA-MIR-6504-3P | 99.17 | 69.31 | 2891 |
| HSA-MIR-7151-3P | 99.04 | 69.72 | 2370 |
| HSA-MIR-6506-5P | 99.04 | 65.66 | 1386 |
| HSA-MIR-4710 | 98.61 | 65.96 | 1048 |
| HSA-MIR-619-5P | 98.57 | 64.97 | 1988 |
| HSA-MIR-5089-5P | 98.45 | 66.06 | 1388 |
| HSA-MIR-4772-3P | 98.04 | 65.60 | 1203 |
| HSA-MIR-665 | 97.60 | 65.64 | 1781 |
| HSA-MIR-6869-5P | 97.17 | 67.06 | 634 |
| HSA-MIR-552-3P | 96.68 | 64.12 | 1026 |
| HSA-MIR-4435 | 95.90 | 65.47 | 1201 |
Literature-anchored findings (GeneRIF, showing 5)
- SC65 protein is identified as an autoimmune target in idiopathic membranous nephropathy. (PMID:23144993)
- High P3H4 expression is associated with bladder cancer. (PMID:30322400)
- Knockdown of P3H4 inhibits proliferation and invasion of bladder cancer. (PMID:32018225)
- P3H4 Overexpression Serves as a Prognostic Factor in Lung Adenocarcinoma. (PMID:34257701)
- P3H4 and PLOD1 expression associates with poor prognosis in bladder cancer. (PMID:35149972)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | p3h4 | ENSDARG00000104089 |
| mus_musculus | P3h4 | ENSMUSG00000006931 |
| rattus_norvegicus | P3h4 | ENSRNOG00000015787 |
| caenorhabditis_elegans | WBGENE00013531 |
Paralogs (1): CRTAP (ENSG00000170275)
Protein
Protein identifiers
Endoplasmic reticulum protein SC65 — Q92791 (reviewed: Q92791)
Alternative names: Leprecan-like protein 4, Nucleolar autoantigen No55, Prolyl 3-hydroxylase family member 4, Synaptonemal complex protein SC65
All UniProt accessions (4): H0YED7, K7EJ03, K7ERA3, Q92791
UniProt curated annotations — full annotation on UniProt →
Function. Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linking of collagen fibrils. Required for normal bone density and normal skin stability via its role in hydroxylation of lysine residues in collagen alpha chains and in collagen fibril assembly.
Subunit / interactions. Interacts with PLOD1, P3H3 and PPIB. Identified in a complex with PLOD1 and P3H3.
Subcellular location. Endoplasmic reticulum.
Tissue specificity. Detected in fibroblasts (at protein level). Detected in spleen, prostate, testis, ovary, colon, pancreas, kidney, placenta and heart.
Similarity. Belongs to the leprecan family.
RefSeq proteins (1): NP_006446* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR011990 | TPR-like_helical_dom_sf | Homologous_superfamily |
| IPR052284 | Collagen_mod_leprecan | Family |
| IPR056585 | Leprecan_dom | Domain |
Pfam: PF23557
UniProt features (7 total): compositionally biased region 2, signal peptide 1, chain 1, region of interest 1, glycosylation site 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q92791-F1 | 83.75 | 0.68 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (1): 361
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 131 (showing top):
GOBP_MEIOTIC_CHROMOSOME_SEGREGATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_COLLAGEN_FIBRIL_ORGANIZATION, GOBP_SYNAPTONEMAL_COMPLEX_ORGANIZATION, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_ORGANELLE_FISSION, MYCMAX_01, GOBP_CHROMOSOME_ORGANIZATION_INVOLVED_IN_MEIOTIC_CELL_CYCLE, GOBP_HOMOLOGOUS_CHROMOSOME_SEGREGATION, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, NERF_Q2, GOBP_PROTEIN_HYDROXYLATION, GOBP_HOMOLOGOUS_CHROMOSOME_PAIRING_AT_MEIOSIS, GOBP_NUCLEAR_CHROMOSOME_SEGREGATION, RIZKI_TUMOR_INVASIVENESS_3D_UP
GO Biological Process (5): synaptonemal complex assembly (GO:0007130), peptidyl-lysine hydroxylation (GO:0017185), collagen fibril organization (GO:0030199), collagen biosynthetic process (GO:0032964), bone remodeling (GO:0046849)
GO Molecular Function (2): protein binding (GO:0005515), collagen binding (GO:0005518)
GO Cellular Component (5): condensed nuclear chromosome (GO:0000794), synaptonemal complex (GO:0000795), nucleolus (GO:0005730), endoplasmic reticulum (GO:0005783), catalytic complex (GO:1902494)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| homologous chromosome pairing at meiosis | 1 |
| cellular component assembly | 1 |
| chromosome organization involved in meiotic cell cycle | 1 |
| synaptonemal complex organization | 1 |
| protein hydroxylation | 1 |
| peptidyl-lysine modification | 1 |
| extracellular matrix organization | 1 |
| biosynthetic process | 1 |
| collagen metabolic process | 1 |
| tissue remodeling | 1 |
| binding | 1 |
| protein-containing complex binding | 1 |
| nuclear chromosome | 1 |
| condensed chromosome | 1 |
| nucleus | 1 |
| synaptonemal structure | 1 |
| nuclear lumen | 1 |
| intracellular membraneless organelle | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| protein-containing complex | 1 |
Protein interactions and networks
STRING
528 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| P3H4 | PPIB | P23284 | 818 |
| P3H4 | PLOD1 | Q02809 | 738 |
| P3H4 | FKBP10 | Q96AY3 | 572 |
| P3H4 | COLGALT1 | Q8NBJ5 | 514 |
| P3H4 | P4HA3 | Q7Z4N8 | 470 |
| P3H4 | PLOD3 | O60568 | 423 |
| P3H4 | SERPINH1 | P29043 | 399 |
| P3H4 | TMEM38B | Q9NVV0 | 397 |
| P3H4 | COL5A2 | P05997 | 375 |
| P3H4 | P4HA2 | O15460 | 357 |
| P3H4 | COLGALT2 | Q8IYK4 | 354 |
| P3H4 | WDR19 | Q8NEZ3 | 349 |
| P3H4 | SLC26A2 | P50443 | 348 |
| P3H4 | CEP290 | O15078 | 348 |
| P3H4 | P4HA1 | P13674 | 346 |
IntAct
79 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| C1QTNF9 | C1QTNF9B | psi-mi:“MI:0914”(association) | 0.780 |
| CCDC120 | AIP | psi-mi:“MI:0914”(association) | 0.640 |
| ZNF397 | ZNF213 | psi-mi:“MI:0914”(association) | 0.640 |
| HRG | PLSCR1 | psi-mi:“MI:0914”(association) | 0.590 |
| OS9 | AGRN | psi-mi:“MI:0914”(association) | 0.530 |
| ALX3 | CRTAP | psi-mi:“MI:0914”(association) | 0.530 |
| C1QTNF9B | PLOD3 | psi-mi:“MI:0914”(association) | 0.530 |
| ADAMTS4 | MANBA | psi-mi:“MI:0914”(association) | 0.530 |
| CHSY3 | CHSY1 | psi-mi:“MI:0914”(association) | 0.530 |
| PLOD3 | PLOD2 | psi-mi:“MI:0914”(association) | 0.530 |
| TAF1C | DNAJA2 | psi-mi:“MI:0914”(association) | 0.530 |
| CPSF6 | DDX39A | psi-mi:“MI:0914”(association) | 0.480 |
| AGPS | psi-mi:“MI:0915”(physical association) | 0.400 | |
| HSCB | RBP5 | psi-mi:“MI:0914”(association) | 0.350 |
| ORF27 | GNPAT | psi-mi:“MI:0914”(association) | 0.350 |
| PLOD1 | COL25A1 | psi-mi:“MI:0914”(association) | 0.350 |
| C1QTNF2 | GNPAT | psi-mi:“MI:0914”(association) | 0.350 |
| CHST8 | CLSTN1 | psi-mi:“MI:0914”(association) | 0.350 |
| COLQ | PLOD2 | psi-mi:“MI:0914”(association) | 0.350 |
| CHSY3 | STK17B | psi-mi:“MI:0914”(association) | 0.350 |
| COLEC10 | PTX3 | psi-mi:“MI:0914”(association) | 0.350 |
| DENND11 | psi-mi:“MI:0914”(association) | 0.350 | |
| CANX | HLA-A | psi-mi:“MI:0914”(association) | 0.350 |
| SFTPA2 | PRPSAP2 | psi-mi:“MI:0914”(association) | 0.350 |
| C1QTNF8 | VWA8 | psi-mi:“MI:0914”(association) | 0.350 |
| RLN1 | RTL8C | psi-mi:“MI:0914”(association) | 0.350 |
| PLOD1 | PLK4 | psi-mi:“MI:0914”(association) | 0.350 |
| CHST8 | CALU | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (94): P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS), P3H4 (Affinity Capture-MS)
ESM2 similar proteins: A2ARS0, A6NH11, A6QQ91, C9JTQ0, D3ZVB0, D4A929, G3MZC5, O75064, O95996, P16386, P46062, P58660, Q02011, Q08DF2, Q16619, Q29RK8, Q2TBW5, Q2VPB7, Q3TAP4, Q3U0S6, Q3U1Y4, Q562E7, Q5TA50, Q5U651, Q60753, Q63086, Q64375, Q68J42, Q6P9B9, Q6ZS72, Q86YV0, Q8BH02, Q8BQU6, Q8C2K5, Q8CHT3, Q8K0R6, Q8K2B0, Q8N9M5, Q8VD26, Q92791
Diamond homologs: O75718, Q32P28, Q3V1T4, Q4KLM6, Q64375, Q6JHU7, Q6JHU8, Q8CG71, Q8IVL5, Q8K2B0, Q90830, Q92791, Q9CYD3, Q9R1J8, Q6PK18, Q8CG70, Q8IVL6, Q5M843, Q5XGE0
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 111 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Collagen biosynthesis and modifying enzymes | 8 | 17.3× | 6e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| collagen fibril organization | 7 | 16.4× | 8e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
75 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 64 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
990 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:41803285:ACCAG:A | donor_gain | 1.0000 |
| 17:41803286:CCAGC:C | donor_gain | 1.0000 |
| 17:41803449:T:TC | acceptor_gain | 1.0000 |
| 17:41806791:CTCA:C | donor_loss | 1.0000 |
| 17:41806792:TCAC:T | donor_loss | 1.0000 |
| 17:41806793:CACCT:C | donor_loss | 1.0000 |
| 17:41806794:A:AC | donor_gain | 1.0000 |
| 17:41806794:AC:A | donor_gain | 1.0000 |
| 17:41806794:ACCT:A | donor_gain | 1.0000 |
| 17:41806795:C:CA | donor_gain | 1.0000 |
| 17:41806795:C:G | donor_loss | 1.0000 |
| 17:41806795:CC:C | donor_gain | 1.0000 |
| 17:41806795:CCT:C | donor_gain | 1.0000 |
| 17:41806795:CCTC:C | donor_gain | 1.0000 |
| 17:41806795:CCTCA:C | donor_gain | 1.0000 |
| 17:41806875:GCCTC:G | acceptor_gain | 1.0000 |
| 17:41806876:CCTCC:C | acceptor_gain | 1.0000 |
| 17:41806877:CTC:C | acceptor_gain | 1.0000 |
| 17:41806878:TC:T | acceptor_gain | 1.0000 |
| 17:41806879:CC:C | acceptor_gain | 1.0000 |
| 17:41806880:C:CA | acceptor_loss | 1.0000 |
| 17:41806880:C:CC | acceptor_gain | 1.0000 |
| 17:41806881:T:G | acceptor_loss | 1.0000 |
| 17:41807854:CCCA:C | donor_loss | 1.0000 |
| 17:41807855:CCA:C | donor_loss | 1.0000 |
| 17:41807856:CACC:C | donor_loss | 1.0000 |
| 17:41807858:C:CG | donor_loss | 1.0000 |
| 17:41807860:T:TA | donor_gain | 1.0000 |
| 17:41807861:C:A | donor_gain | 1.0000 |
| 17:41807875:T:TA | donor_gain | 1.0000 |
AlphaMissense
2852 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:41807967:G:C | S318R | 0.999 |
| 17:41807967:G:T | S318R | 0.999 |
| 17:41807969:T:G | S318R | 0.999 |
| 17:41809719:A:C | F301L | 0.999 |
| 17:41809719:A:T | F301L | 0.999 |
| 17:41809721:A:G | F301L | 0.999 |
| 17:41809726:A:G | L299P | 0.999 |
| 17:41809798:C:T | C275Y | 0.999 |
| 17:41809797:A:C | C275W | 0.998 |
| 17:41811689:C:T | C76Y | 0.998 |
| 17:41809720:A:C | F301C | 0.997 |
| 17:41809798:C:A | C275F | 0.997 |
| 17:41809798:C:G | C275S | 0.997 |
| 17:41809799:A:G | C275R | 0.997 |
| 17:41809799:A:T | C275S | 0.997 |
| 17:41810916:C:T | C245Y | 0.997 |
| 17:41810981:G:C | S223R | 0.997 |
| 17:41810981:G:T | S223R | 0.997 |
| 17:41810983:T:G | S223R | 0.997 |
| 17:41811500:A:G | F139S | 0.997 |
| 17:41811689:C:G | C76S | 0.997 |
| 17:41811690:A:T | C76S | 0.997 |
| 17:41811760:C:A | W52C | 0.997 |
| 17:41811760:C:G | W52C | 0.997 |
| 17:41811026:G:C | F208L | 0.996 |
| 17:41811026:G:T | F208L | 0.996 |
| 17:41811027:A:C | F208C | 0.996 |
| 17:41811027:A:G | F208S | 0.996 |
| 17:41811028:A:G | F208L | 0.996 |
| 17:41811500:A:C | F139C | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1001731014 (17:41808211 T>C), RS1002053633 (17:41802627 C>T), RS1002288350 (17:41812783 G>A), RS1002778833 (17:41810249 A>C,G), RS1003919189 (17:41813917 C>T), RS1004965490 (17:41808149 G>A), RS1004994006 (17:41802035 C>T), RS1005282793 (17:41802365 C>T), RS1005520682 (17:41805387 C>T), RS1005578712 (17:41807799 C>A), RS1005677985 (17:41804950 G>A), RS1005882099 (17:41803698 C>G,T), RS1006174019 (17:41809546 G>A), RS1006530557 (17:41806704 G>A), RS1006814689 (17:41811991 C>A,G)
Disease associations
OMIM: gene MIM:617419 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002279_98 | PR interval in Tripanosoma cruzi seropositivity | 3.000000e-08 |
| GCST007269_303 | Pulse pressure | 7.000000e-09 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004462 | PR interval |
| EFO:0005763 | pulse pressure measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
36 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, decreases expression, increases methylation | 5 |
| bisphenol A | decreases expression, increases expression | 2 |
| sodium arsenite | decreases expression | 2 |
| perfluorooctanoic acid | decreases expression | 2 |
| Tobacco Smoke Pollution | affects expression, decreases expression | 2 |
| Aflatoxin B1 | decreases expression, increases methylation | 2 |
| Particulate Matter | decreases expression, increases abundance, increases expression | 2 |
| testosterone enanthate | affects expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| cupric chloride | affects expression | 1 |
| beta-methylcholine | affects expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| abrine | decreases expression | 1 |
| 2,2’,4,4’-tetrabromodiphenyl ether | decreases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Vehicle Emissions | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Copper | affects binding, increases expression | 1 |
| Diethylhexyl Phthalate | decreases expression | 1 |
| Disulfiram | affects binding, increases expression | 1 |
| Hydrogen Peroxide | affects expression | 1 |
| Ivermectin | decreases expression | 1 |
| Plant Oils | decreases expression | 1 |
| Smoke | decreases expression | 1 |
| Thiram | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.